Almada

• A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni … Ended
  2023-505755-40-00 4 2024-08-16 Chronic kidney disease
• A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arteri … Ended
  2022-502378-17-00 4 2024-03-20 Pulmonary Arterial Hypertension
• Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP. Ended
  2024-512646-42-00 4 2023-06-27 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL) Ended
  2023-508735-31-00 5 2023-05-05 Pulmonary Arterial Hypertension (PAH)
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended
  2022-501538-44-00 5 2023-04-25 Atopic Dermatitis
• Prophylaxis of venous thromboembolic disease with LMWH (TINzaparin) in patients with metastatic colorectal cancer who start the first line o … Ended
  2023-508860-31-00 5 2023-02-28 Stage IV colon or rectal adenocarcinoma (mCRC).
• A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509783-23-00 4 2023-02-24 Diffuse Cutaneous Systemic Sclerosis
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptoms Ended
  2022-500332-11-00 4 2022-11-25 systemic sclerosis
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• A research study to look into how semaglutide, together with a lower dose of insulin glargine, compares to a higher dose of insulin glargine … Ended
  2024-510612-75-00 5 2022-08-31 Participants with T2D and overweight
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and … Ended
  2023-508734-34-00 10 2022-06-30 Pulmonary Arterial Hypertension (PAH)
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of RO7303509 in Patients with Systemic Sclero … Ended
  2022-502981-26-00 3 2022-06-27 Systemic Sclerosis
• A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension (PAH) Patients. Ended
  2023-509139-16-00 5 2022-05-13 Therapeutic confirmatory (phase III)
• A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) Ended
  2024-514372-40-00 5 2022-04-12 Anterior ST-Elevation Myocardial Infarction
• A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509782-20-00 4 2021-11-11 Diffuse Cutaneous Systemic Sclerosis
• A trial to learn how well finerenone works and how safe it is in adult participants with non-diabetic chronic kidney disease Ended
  2023-506897-11-00 5 2021-10-18 Non-diabetic chronic kidney disease
• Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab in chronic obstructive pulmonary disease (COPD) (AER … Ended
  2024-512012-21-00 5 2021-04-08 Chronic Obstructive Pulmonary Disease
• A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MY … Ended
  2022-502858-14-00 5 2019-09-05 Hypertrophic cardiomyopathy
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok

Showing 73–92 of 92 trials